-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Platelet Transfusions for Hematology / Oncology Patients: Taking a More Granular Look - Live Q&A

Program: Education Program
Sunday, December 6, 2020: 9:30 AM-10:15 AM

Description:
This session will address key issues in the use of platelet transfusion therapy to prevent and treat bleeding in patient with hematology oncology disorders. Prophylactic platelet transfusions are widely used in patients with severe thrombocytopenia however significant breakthrough bleeding occurs.

Dr Darrell Triulzi will present data supporting this practice, limitations of prophylactic platelet transfusions, and new approaches to reduce breakthrough bleeding. A complication of platelet transfusion therapy is refractoriness characterized by a suboptimal response to platelet transfusion.

Dr Nancy Dunbar will explore the role of platelet ABO and RhD matching in platelet transfusions. Specifically we will explore the impact of major ABO incompatibility on count increments, the risks for hemolysis associated with minor ABO incompatibility and the risk of Rh alloimmunization when Rh negative patients receive Rh positive platelet transfusions.

Dr Claudia Cohn will cover the diagnosis of a platelet-refractory patient and an exploration of the immune-mediated causes for this state. Issues related to patient management will include selection of compatible platelets, laboratory tests related to platelet selection and the various clinical and laboratory factors that may influence the patient's response to platelet transfusions.Patients with immune-mediated platelet refractoriness require special management strategies.

Chair:
Darrell J Triulzi, MD , Institute for Transfusion Medicine
Disclosures:
Triulzi: Fresenius Kabi: Consultancy; Cerus Corp: Research Funding.
Panelists:
Darrell J Triulzi, MD , UPMC , Nancy M. Dunbar, MD, Dartmouth and Claudia S. Cohn, MD, PhD, University of Minnesota
Disclosures:
Triulzi: Fresenius Kabi: Consultancy; Cerus Corp: Research Funding. Dunbar: Verax Biomedical: Membership on an entity's Board of Directors or advisory committees.
This session will address key issues in the use of platelet transfusion therapy to prevent and treat bleeding in patient with hematology oncology disorders. Prophylactic platelet transfusions are widely used in patients with severe thrombocytopenia however significant breakthrough bleeding occurs.

Dr Darrell Triulzi will present data supporting this practice, limitations of prophylactic platelet transfusions, and new approaches to reduce breakthrough bleeding. A complication of platelet transfusion therapy is refractoriness characterized by a suboptimal response to platelet transfusion.

Dr Nancy Dunbar will explore the role of platelet ABO and RhD matching in platelet transfusions. Specifically we will explore the impact of major ABO incompatibility on count increments, the risks for hemolysis associated with minor ABO incompatibility and the risk of Rh alloimmunization when Rh negative patients receive Rh positive platelet transfusions.

Dr Claudia Cohn will cover the diagnosis of a platelet-refractory patient and an exploration of the immune-mediated causes for this state. Issues related to patient management will include selection of compatible platelets, laboratory tests related to platelet selection and the various clinical and laboratory factors that may influence the patient's response to platelet transfusions.Patients with immune-mediated platelet refractoriness require special management strategies.

See more of: Education Program
<< Previous Session | Next Session >>